Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis

Study Overview
=================
Brief Summary
-----------------
Objective of this study is to investigate the intracameral level of ganciclovir following topical application of 0.15% ganciclovir gel (VIRGAN©) for Cytomegalovirus (CMV) anterior uveitis and endothelitis. Thirty patients who are diagnosed with CMV anterior segment infection, either uveitis or endothelitis, who have a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for CMV and have not had any form of ganciclovir treatment in the past 1 month, will be recruited in the study after taking an informed consent. with active CMV anterior segment infection confirmed by a positive aqueous real time PCR (RT-PCR) and have not had any form of ganciclovir treatment in the past 1 month were recruited in the study. Patients were given 0.15% ganciclovir gel 1cc 5 times a day for 6 weeks. Following 6 weeks of treatment, tears and aqueous samples will be collected. Aqueous will be sent for RT-PCR for CMV status. Ganciclovir drug level in both tears and aqueous will be measured by HPLC method. Clinically, degree of the intraocular inflammation, Intraocular pressure (IOP) and central corneal thickness (CCT) will be recorded at baseline and post-treatment.

Official Title
-----------------
Intra-cameral Penetration of Ganciclovir Following Topical Administration of 0.15% Ganciclovir Gel (VIRGAN©) for CMV Anterior Uveitis / Endotheliitis

Conditions
-----------------
Cytomegalovirus Anterior Segment Infection, Anterior Uveitis, Endotheliitis

Intervention / Treatment
-----------------
* Drug: Ganciclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 21 and above Patients who are diagnosed with anterior uveitis or endotheliitis with a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for Cytomegalovirus (CMV) Patients with relapses and recurrent anterior segment disease that is PCR positive for CMV in aqueous Have not been on VIRGAN or any other form of ganciclovir therapy for the past 1 month Consent to undergo anterior chamber tap and give aqueous and tear samples for the study Able to undergo relevant tests (corneal pachymetry and laser flare cell photometry) Able to come for subsequent follow-up visits Exclusion Criteria: CMV anterior uveitis with associated retinitis Other causes of hypertensive anterior uveitis / endotheliitis such as HSV, VZV infection Patients who have been on any form of (topical, local or systemic) ganciclovir therapy for the past1 month. Patients who are allergic to ganciclovir Patients who will require systemic or intra-vitreal ganciclovir therapy Immunocompromised patients Positive for HIV, Hep B and Hep C Not keen on participating in the study Patients who are incapable, either by law or mental state, of giving consents in their own right. Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol Patients who are pregnant or breastfeeding Any other specified reason as determined by the clinical investigator.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ganciclovir<br>Treatment with topical ganciclovir ointment | Drug: Ganciclovir<br>* Treatment with topical ganciclovir ointment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Median concentration of ganciclovir in anterior chamber and ocular surface | Following 6 weeks of continuous application of Virgan gel 0.15% 1cc 5 times a day, the patient will be reviewed at the clinic within 3 hours following the last application of the gel. | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of intracameral concentration of virgan with the corneal thickness |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytomegalovirus, uveitis, endotheliitis, ganciclovir